DEF: PROCEPT BioRobotics 2026 Annual Meeting Proxy Statement

PROCEPT BioRobotics Corporation has issued its 2026 proxy statement detailing director elections, executive compensation, and the ratification of its independent auditor.

Summary

• The 2026 Annual Meeting of Stockholders is scheduled for June 9, 2026, in a virtual-only format.
• Stockholders will vote on the election of three Class II directors: Antal Desai, Mary Garrett, and Frederic Moll, M.D.
• The company seeks ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026.
• An advisory vote on the compensation of named executive officers (NEOs) is included.
• The company reported 2025 revenue of $308.1 million, a 37% increase over 2024.
• U.S. procedures performed using company systems reached approximately 43,300 in 2025, up 56% from 2024.
• The U.S. installed base of systems grew to 718, a 42% increase year-over-year.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive filing; while financial performance missed internal bonus targets, the company demonstrated strong top-line growth and successfully executed a major leadership transition.

Positives

• Revenue grew 37% to $308.1 million in 2025.
• U.S. procedure volume increased 56% to approximately 43,300.
• Installed base of robotic systems increased 42% to 718 units.
• Gross margins improved to 64% in 2025 from 61% in 2024.
• FDA clearance received for the HYDROS Robotic System.
• Strong stockholder support for executive compensation, with over 95% approval in the 2025 say-on-pay vote.

Negatives

• Revenue performance for 2025 was below the minimum payout level established in the bonus plan.
• The company reported a net loss of $95.6 million for 2025.
• The 2025 PSU revenue goal was certified at 0% achievement, resulting in no payout for that component.
• The company experienced a leadership transition with the retirement of the former CEO and the elimination of the Chief Commercial Officer role.

Risks

• Potential for failure to achieve future performance goals linked to executive compensation.
• Risks associated with the integration of new leadership and the restructuring of commercial operations.
• Cybersecurity risks and the need for ongoing management of information systems.
• Dependence on the successful adoption of the HYDROS Robotic System.
• Market competition and the ability to maintain growth in the medical device sector.

Future Outlook

The company is focused on scaling its robotic solutions, expanding into new indications such as prostate cancer, and leveraging the newly cleared HYDROS Robotic System to drive future growth.

Management Comments

• The Board believes that separating the CEO and Chair positions reinforces independence and objective oversight.
• The Board identified Larry L. Wood as uniquely qualified to serve as CEO due to his extensive experience in scaling disruptive medical device businesses.
• The Compensation Committee exercised discretion to approve an 80% payout level for 2025 company performance goals despite revenue falling below the minimum threshold, citing progress against other strategic objectives.

Industry Context

StockSavvy.ai notes that PROCEPT BioRobotics is operating in a high-growth segment of the medical device industry, specifically robotic-assisted urology. The company's transition to a new CEO with significant industry experience mirrors trends among mid-cap medical technology firms seeking to scale operations and improve commercial execution.

Comparison to Industry Standards

• The company's executive compensation program utilizes a peer group of 17 companies, including AtriCure, Glaukos, and Penumbra, to benchmark pay.
• The use of a 95% at-risk compensation structure for the CEO is consistent with high-growth medical technology industry standards.
• The company's clawback policy and stock ownership requirements align with current best practices in corporate governance for public companies.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• The company is party to an amended and restated investor rights agreement with certain stockholders, directors, and executive officers.

Stakeholder Impact

• Shareholders are asked to vote on director elections, auditor ratification, and executive compensation.
• Employees are impacted by the ongoing restructuring of commercial leadership and the company's growth trajectory.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on June 9, 2026.
• File final voting results in a Form 8-K within four business days after the meeting.
• Continue the transition consulting role for former CEO Dr. Reza Zadno for up to 18 months.

Key Dates

Recommendation

The company shows strong growth metrics but missed internal performance targets, and is currently in a period of leadership transition. A hold recommendation is appropriate until the new CEO's strategy and the impact of the commercial restructuring are fully realized.

Keywords

PROCEPT BioRobotics, PRCT, Proxy Statement, Medical Devices, Robotic Surgery, Executive Compensation, Corporate Governance, BPH Treatment